假肢功能障碍后bevacizumab:一个跨导管大动脉置换血栓的病例报告
Denise Mourad1, Sachin Singh1, Fahd Mohamed2
1Department of Internal Medicine, Central Michigan University, 1015 S. Washington Avenue, Saginaw, MI 48601, USA.
过导管大动脉置换 (TAVR) 血栓可能与贝瓦齐祖马布 (bevacizumab) 相关,贝瓦齐祖马布是一种血管内皮生长因子 (VEGF) 抑制剂. 及时停止药物和抗凝固药物正常化了TAVR患者的门功能.
科学领域:
- 心脏病学 心脏病学
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 透导管大动脉置换 (TAVR) 血栓是已知的并发症.
- TAVR血栓形成和血管内皮生长因子 (VEGF) 抑制剂之间的关联仍然未被探索.
更多相关视频
06:59Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation
Published on: June 3, 2018
06:02Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
相关概念视频
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse III: Nursing Management
Mitral Valve Prolapse I: Introduction
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Venous Thrombosis III: Interprofessional Care
